Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 29;7:125. doi: 10.1038/s41420-021-00504-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A–B CCK8 assay showed that combined avasimibe and etomoxir enhanced the efficacy in the HepG2 and HUH7 (means ± SEM, n = 3). Chou and Talalay analyzed the combination indices (CI) of combined AVA and ETO for 48 h in HepG2 and HUH7. The straight line at CI = 1 represents the additive effects of both drugs. Fraction effect (FA): growth inhibition rate. C Representative images of the EdU staining assay in HUH7 cells treated with AVA, ETO, or both. D The colony formation assay of HepG2 and HUH7 cells cultured with 2 μM AVA and/or 25 μM ETO for 14 days. E Western blot analysis of CDK4, CDK6, and Cyclin D1 in HepG2 and HUH7 cells treated with 20 μM AVA and/or 150 μM ETO. F Western blot analysis of CyclinD1, CPT1A, and SOAT1 after transfection with si-SOAT1and/or si-CPT1A in PLC/PCF/5 and HUH7. G–I Levels of total acetyl-CoA, ATP and β-hydroxybutyrate in HCC cells treated with AVA (5 μM) and/or ETO (50 μM) (mean ± SEM, n = 3); *p < 0.05, **p < 0.01, ***p < 0.001; ns: no significance. J Levels of intrahepatic FFAs in HepG2 and HUH7 treated with AVA (5 μM) and/or ETO (50 μM) (mean ± SEM, n = 3); *p < 0.05.